Mirati Therapeutics
9363 Towne Centre Drive
Suite 200
San Diego
California
92121
United States
Tel: 858-535-2075
311 articles about Mirati Therapeutics
-
New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases
6/6/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results of a prospective analysis from the Phase 1b cohort of the KRYSTAL-1 study evaluating intracranial (IC) responses of adagrasib in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) with active and untreated central nervous system (CNS) metastases.
-
Mirati Therapeutics' adagrasib is going up against Amgen’s Lumakras in the KRAS race, and according to Friday pre-market trading, the results shared Thursday don't seem to be enough for investors.
-
Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
5/26/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID in patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.
-
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences in June 2022
5/25/2022
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.
-
Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer
5/19/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.
-
Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
5/16/2022
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced the appointment of Laurie Stelzer as the Company's Chief Financial Officer effective May 16, 2022.
-
Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates
5/4/2022
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, reported financial results for the first quarter of 2022 and recent corporate updates.
-
Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib
4/27/2022
Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibitor, adagrasib, in a study of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Mirati Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Updates
4/20/2022
Mirati Therapeutics, Inc. will announce financial results for the first quarter of 2022 along with recent corporate updates on May 4, 2022.
-
Mirati Therapeutics to Participate in the 42nd Annual Cowen Healthcare Conference
3/2/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Cowen Healthcare Conference.
-
Mirati Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates
2/28/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year 2021 and recent corporate updates.
-
The NDA acceptance is based on positive results from the KRYSTAL-1 trial, which looked into the effect of using 600mg BID of adagrasib in patients.
-
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
2/15/2022
Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.
-
Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2021 and Recent Corporate Updates on February 28, 2022
2/14/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the fourth quarter and full year of 2021 along with recent corporate updates on February 28, 2022.
-
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
2/2/2022
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.
-
Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers
1/21/2022
Mirati Therapeutics, Inc. today announced positive results from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in patients with pretreated pancreatic ductal adenocarcinoma and other gastrointestinal (GI) tumors harboring a KRAS mutation.
-
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
-
Mirati Therapeutics to Present at the J.P. Morgan 40th Annual Virtual Healthcare Conference
1/4/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will present at the J.P. Morgan 40th Annual Virtual Healthcare Conference, on Monday, January 10, 2022.
-
Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
11/23/2021
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Evercore ISI HealthCONx Conference.
-
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
11/22/2021
Mirati Therapeutics, Inc. announced a non-exclusive clinical collaboration agreement to evaluate the combination of Mirati's investigational KRASG12C inhibitor adagrasib with Verastem Oncology's investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer.